Updated on 7 July 2014
With 11 percent share and $11.65 billion is revenue, Australia grew marginally.
It has been a bad year or Australia's top three companies which nearly account for almost 77 percent of the total revenue generated by Australia's bioscience companies.
While CSL registered six percent growth, Sigma Pharmaceuticals and ResMed recorded six percent decline and zero percent growth respectively.
Australia has only three companies that have in excess of $1 billion in revenue.